(E)-2-Methoxyimino-2-oxobutyric acid, 1,1-dimethylethyl ester

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 英文名称: (E)-2-Methoxyimino-2-oxobutyric acid, 1,1-dimethylethyl ester
• 英文别名: tert-butyl (2E)-2-methoxyimino-3-oxobutanoate
• 化学式: C₉H₁₅NO₄
• 分子量: 201.22
• InChiKey: NGQMPYHAZGBVKN-JXMROGBWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  65
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (E)-2-Methoxyimino-2-oxobutyric acid, 1,1-dimethylethyl ester 生成 (Z)-2-(Methoxyimino)-3-oxo-butanoic Acid
  参考文献：
  名称：

  NAJTO, KEHNDZO;ISIXASI, YUKIO;SINSUKEH, XARUO

  摘要：

  DOI：

文献信息

• Process for the preparation of cephalosporin intermediate and its use for the manufacture of cephalosporin compounds
  申请人：Orchid Chemicals and Pharmaceuticals Limited

  公开号：US20030199712A1

  公开（公告）日：2003-10-23

  The present invention relates to a process for the preparation of 4-halogeno-2-substitutedimino-3-oxo-butyric acid of formula (I) 1 wherein R 1 represents CH 3 , CR a R b COOR c where R a and R b independently represent hydrogen or methyl and R c represents hydrogen or (C 1 -C 6 )alkyl, X represents halogen such as chlorine or bromine, also discloses the activation of this acid and its further use in the preparation of cephalosporanic antibiotics (II) in excellent yields and purity

  本发明涉及一种制备式(I)的4-卤代-2-取代亚胺-3-氧代丁酸的方法，其中R1代表CH3，CRaRbCOORc，其中Ra和Rb独立地代表氢或甲基，Rc代表氢或(C1-C6)烷基，X代表卤素如氯或溴，同时还揭示了该酸的活化以及其在制备头孢菌素类抗生素(II)中的进一步应用，产率高，纯度高。
• Method for manufacture of ceftriaxone sodium
  申请人：Datta Debashish

  公开号：US20050059820A1

  公开（公告）日：2005-03-17

  An improved process for preparation of ceftriaxone sodium of formula (II), is disclosed.

  公开了一种改进的制备式（II）头孢曲松钠的方法。
• Process for the preparation of N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene) methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
  申请人：Ratiopharm GmbH

  公开号：EP2264027A1

  公开（公告）日：2010-12-22

  The present invention relates to processes for the preparation of N-[2-(Diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carbox- amide of formula (VI).

  本发明涉及制备公式（VI）的N-[2-（二乙氨基）乙基]-5-[(5-氟-1,2-二氢-2-氧代-3H-吲哚-3-基)甲基]-2,4-二甲基-1H-吡咯-3-甲酰胺的方法。
• Chemical compounds
  申请人：Ratcliffe James Andrew

  公开号：US20050009831A1

  公开（公告）日：2005-01-13

  The present invention concerns compounds of general formula (I): in which: R 1 represents hydrogen, R 4 , —C(═Y)—NHR 4 , —SO 2 NHR 4 , —C(=Z 1 )—R 4 , —SO 2 —R 4 or —C(=Z 1 )—OR 4 ; R 2 represents hydrogen, cyano, halogen or —C≡C—R 5 ; R 3 represents hydrogen, acyl, alkoxycarbonyl, alkyl, aroyl, aryl, aryloxycarbonyl, carboxy, cycloalkenyl, cycloalkyl, heteroaroyl, heteroaryl, heterocycloalkyl or —C(═O)—NY 1 Y 2 ; R 4 represents optionally substituted alkyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl or heteroaryl R 5 represents hydrogen or alkyl; R 6 represents alkyl, acyl, alkoxycarbonyl, alkylsulfonyl, aryl, arylsulfonyl, aroyl, cycloalkyl, cycloalkenyl, heteroaryl, heteroarylsulfonyl, heteroaroyl and heterocycloalkyl; R 7 represents optionally substituted alkyl, cycloalkyl or cycloalkylalkyl, R 8 represents hydrogen, alkyl, alkenyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl; R 9 represents alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl; R 10 represents hydrogen or lower alkyl; R 11 represents alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl; or alkyl optionally substituted by —NY 1 Y 2 ; R 12 represents aryl or heteroaryl; or alkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl or heterocycloalkylalkyl each optionally substituted Y represents O, S or NCN; Y 1 and Y 2 (Y 3 and Y 4 ) are independently in particular hydrogen, alkyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl or heterocycloalkyl; or the group —NY 1 Y 2 may form 5-7 membered ring or the group —NY 3 Y 4 (—NY 5 Y 6 ) may form a cyclic amine; Z (Z 1 ) represents O or S; Z 2 represents O or S(O) p ; n is zero or an integer 1 or 2; m is 1 or 2; p is 1 or 2; and their corresponding N-oxides, their prodrugs; their pharmaceutically acceptable salts and solvates (e.g. hydrates), also together with one or more pharmaceutically acceptable carriers or excipients, such novel indolizines derivatives with inhibitory effects towards kinase proteins and especially for use for preventing or treating diseases that may be modulated by the inhibition of such kinase proteins and particularly solid tumours.

  本发明涉及通式（I）的化合物： 其中： R1代表氢，R4，—C（═Y）—NHR4，—SO2NHR4，—C（=Z1）—R4，—SO2—R4或—C（=Z1）—OR4； R2代表氢，氰基，卤素或—C≡C—R5； R3代表氢，酰基，烷氧羰基，烷基，芳酰基，芳基，芳氧羰基，羧基，环烯基，环烷基，杂芳酰基，杂芳基，杂环烷基或—C（═O）—NY1Y2； R4代表可选取代的烷基，环烷基，环烯基，杂环烷基，芳基或杂芳基； R5代表氢或烷基； R6代表烷基，酰基，烷氧羰基，烷基磺酰基，芳基，芳基磺酰基，芳酰基，环烷基，环烯基，杂芳基，杂芳基磺酰基，杂芳酰基和杂环烷基； R7代表可选取代的烷基，环烷基或环烷基烷基； R8代表氢，烷基，烯基，芳基，芳基烷基，杂芳基或杂芳基烷基； R9代表烷基，芳基，芳基烷基，环烷基，环烷基烷基，杂芳基，杂芳基烷基，杂环烷基或杂环烷基烷基； R10代表氢或较低的烷基； R11代表烷基，芳基，芳基烷基，环烷基，环烷基烷基，杂芳基，杂芳基烷基，杂环烷基或杂环烷基烷基；或可选取代的烷基，被—NY1Y2取代； R12代表芳基或杂芳基；或可选取代的烷基，环烷基，环烷基烷基，杂环烷基或杂环烷基烷基； Y代表O，S或NCN； Y1和Y2（Y3和Y4）特别是独立的氢，烷基，芳基，环烷基，环烯基，杂芳基或杂环烷基；或该基团—NY1Y2可能形成5-7成员环或该基团—NY3Y4（—NY5Y6）可能形成一个环状胺； Z（Z1）代表O或S； Z2代表O或S（O）p； n为零或整数1或2； m为1或2； p为1或2； 以及它们对应的N-氧化物，它们的前药；它们的药物可接受的盐和溶剂化合物（例如水合物），还包括一个或多个药物可接受的载体或赋形剂，这种新的吲哚嗪衍生物具有对激酶蛋白的抑制作用，特别是用于预防或治疗可能通过抑制这种激酶蛋白而调节的疾病，特别是固体肿瘤。
• METHOD FOR THE MANUFACTURE OF CEFTRIAXONE SODIUM
  申请人：Datta Debashish

  公开号：US20080200670A1

  公开（公告）日：2008-08-21

  An improved process for preparation of ceftriaxone sodium of formula (II), is disclosed.

  本发明揭示了一种改进的制备式(II)头孢曲松钠的方法。